SAN DIEGO, May 7, 2026
Halozyme Therapeutics, Inc. announced a major global collaboration and license agreement with GSK to develop subcutaneous formulations for multiple oncology therapies, including antibody-drug conjugates (ADCs), using Halozyme’s proprietary ENHANZE® drug delivery technology. The partnership represents a significant advancement in cancer treatment innovation and marks the first ENHANZE collaboration focused on ADC targets, highlighting growing pharmaceutical industry interest in improving cancer therapy delivery and reducing treatment burden for patients.
Under the terms of the agreement, GSK gains access to Halozyme’s ENHANZE® platform to support development and potential commercialization of several oncology products delivered through subcutaneous injection instead of traditional intravenous administration. The collaboration also includes options for additional future therapeutic targets, potentially expanding the partnership further across GSK’s oncology pipeline. The companies expect the first clinical trial under the collaboration to begin in 2026, signaling rapid progression toward clinical development activities.
ENHANZE® Technology Targets Faster and Easier Cancer Care
Halozyme’s ENHANZE® technology is designed to enable rapid, large-volume subcutaneous delivery of biologics and injectable medicines, helping simplify treatment administration while improving patient convenience. The platform uses the company’s proprietary rHuPH20 enzyme to facilitate dispersion and absorption of injected therapies beneath the skin, potentially reducing lengthy infusion times commonly associated with cancer treatments.
The collaboration is particularly notable because it expands ENHANZE® into the rapidly growing ADC therapeutic category, an area attracting major investment across the oncology industry. ADCs combine targeted antibodies with potent cancer-fighting agents, allowing more precise delivery of treatment to tumor cells while minimizing damage to healthy tissue. By exploring subcutaneous formulations for ADCs, Halozyme and GSK aim to improve the benefit-risk profile, patient experience and accessibility of advanced oncology therapies.
Advertisement
Dr. Helen Torley, President and Chief Executive Officer of Halozyme, stated that the agreement reinforces ENHANZE® as the industry’s leading platform for subcutaneous drug delivery. She emphasized that integrating the technology with ADCs could significantly expand Halozyme’s addressable market while strengthening the company’s high-margin royalty business model. According to Torley, the partnership demonstrates continued confidence from major pharmaceutical companies in Halozyme’s ability to support next-generation oncology drug delivery solutions.
GSK Focuses on Reducing Treatment Burden in Oncology
GSK executives highlighted the growing importance of more patient-friendly treatment approaches in cancer care. Eric Richards, SVP and Head of Medicine Development Leaders Oncology at GSK, said the company sees strong potential for subcutaneous oncology formulations that can improve treatment accessibility and reduce patient burden associated with lengthy clinic visits and infusion procedures.
The agreement includes an upfront payment from GSK to Halozyme, along with potential milestone payments tied to development and commercialization achievements. Halozyme will also receive royalties on future net sales of products developed using ENHANZE® technology. Financial details of the deal were not disclosed publicly.
Industry analysts view the collaboration as another important validation of the expanding role of drug delivery technologies in precision oncology and biologics development. Subcutaneous administration is increasingly being explored by pharmaceutical companies seeking to improve adherence, convenience and healthcare efficiency while reducing administration time and resource utilization in hospitals and infusion centers.
Halozyme Expands Leadership in Drug Delivery Innovation
Halozyme continues broadening its technology portfolio beyond ENHANZE®, including development of its Hypercon™ microparticle technology and integration of Surf Bio’s polymer-based hyperconcentration platform. These technologies are designed to support delivery of highly concentrated biologics through smaller injection volumes, potentially enabling at-home treatment administration and expanded therapeutic applications.
The company already partners with several major pharmaceutical organizations, including Roche, Pfizer, Takeda, Bristol Myers Squibb, Eli Lilly, Janssen and AbbVie, among others. More than one million patients worldwide have received therapies enabled by ENHANZE® across over 100 international markets, underscoring the growing adoption of advanced subcutaneous drug delivery systems in modern medicine.
As competition intensifies in oncology innovation, collaborations such as the Halozyme-GSK agreement are expected to accelerate development of more convenient and patient-centered cancer therapies, particularly in fast-growing areas like ADC-based treatments and biologic drug delivery.
Source: Halozyme, GSK press release
